Mira Pharmaceuticals Inc MIRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy
-
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
-
MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN
-
MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2
-
MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate
-
MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies
Trading Information
- Previous Close Price
- $0.98
- Day Range
- $0.95–0.97
- 52-Week Range
- $0.90–2.45
- Bid/Ask
- $0.95 / $0.97
- Shares Outstanding
- 42.02M
- Market Cap
- $39.97M
- Volume/Avg
- 32,814 / 150,763
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Small Growth
- Total Number of Employees
- 2
Valuation
|
Metric
|
MIRA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.23 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MIRA
|
|---|---|
Quick Ratio | 81.97 |
Current Ratio | 82.16 |
Interest Coverage | — |
Quick Ratio
MIRA
Profitability
|
Metric
|
MIRA
|
|---|---|
Return on Assets (Normalized) | −69.98% |
Return on Equity (Normalized) | −73.11% |
Return on Invested Capital (Normalized) | −75.21% |
Return on Assets
MIRA
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Fnncqkgt | Mhz | $992B | |||
| Johnson & Johnson
JNJ
| Fbblzkqr | Csm | $564B | |||
| AbbVie Inc
ABBV
| Pgrcdnz | Mwsr | $391B | |||
| Roche Holding AG ADR
RHHBY
| Ngglmrms | Wmxp | $329B | |||
| Novartis AG ADR
NVS
| Cfkfysjhtq | Cwwj | $291B | |||
| Merck & Co Inc
MRK
| Yrktcscxv | Tzby | $285B | |||
| AstraZeneca PLC
AZN
| Ghcyylmhv | Gnzr | $280B | |||
| Novo Nordisk AS ADR
NVO
| Hxqykccqz | Gmfb | $196B | |||
| Amgen Inc
AMGN
| Qykkpbtxhn | Fgmtc | $184B | |||
| Gilead Sciences Inc
GILD
| Tbkckbz | Bmt | $156B |
United States